Loading
This study assigned extra treatment after surgery using blood and tumour tests. It stopped and is no longer an access route.
Registry status terminated, last updated 2025-05-31. Enrollment is 52 actual. Residual early TNBC after neoadjuvant therapy and definitive resection. The ctDNA-enriched, genomically directed platform included talazoparib/capecitabine and inavolisib/capecitabine strategies, with pembrolizumab rules differing by assigned arm. The registry states termination for a funder decision; that administrative reason is not an efficacy result.
Shares PARP, Capecitabine, Triple-negative breast cancer (TNBC), Pembrolizumab.
Shares Talazoparib, PARP, Triple-negative breast cancer (TNBC).
Shares Talazoparib, PARP, Triple-negative breast cancer (TNBC).
Shares Talazoparib, PARP.
Shares PARP, Triple-negative breast cancer (TNBC).
Shares Talazoparib, PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/